DCM
BBIO icon

Dupont Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Dupont Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,231
Closed -$62.7K – 797
2022
Q4 		$62.7K Sell
8,231
-883
-10% -$8.45K ﹤0.01% 1032
2022
Q3 		$91K Buy
+9,114
New +$94.7K 0.01% 1073

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Dupont Capital Management's BBIO Position: Q1 2023 in Review

Dupont Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2023, closing a stake of 8,231 shares — an estimated $62.7K sold.

Dupont Capital Management first reported a position in BBIO in Q3 2022 and held it in 2 quarters. The position peaked at $91K in Q3 2022. 213 funds tracked by Wall St. Rank hold BBIO as of Q1 2023.

  • Dupont Capital Management reported no remaining BridgeBio Pharma position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 8,231 BridgeBio Pharma shares in Q1 2023, an estimated $62.7K.
  • Dupont Capital Management first reported a position in BridgeBio Pharma in Q3 2022 and held it in 2 quarters.
  • Dupont Capital Management's BridgeBio Pharma position peaked at $91K in Q3 2022.
  • 213 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.